{"id":"W2335244965","doi":"10.1200/jco.2007.25.18_suppl.14018","title":"A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cetuximab; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Irinotecan; Urology; Pharmacokinetics; Pharmacology; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002091038,0.0002012646,0.001552494,0.0004250481,0.00002109966,0.000007914154,0.0001125178,0.0000928109,0.0000143034],"category_scores_gemma":[0.0006676315,0.0001344591,0.00007562187,0.0004375606,0.0001951076,0.0002500897,0.0000449731,0.000504756,1.809127e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001515096,"about_ca_system_score_gemma":0.000353522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009621489,"about_ca_topic_score_gemma":0.001505433,"domain_scores_codex":[0.9965997,0.0002599874,0.002072749,0.0002455713,0.0005453372,0.0002766917],"domain_scores_gemma":[0.9965929,0.0005321153,0.001875223,0.0001623588,0.00065641,0.0001809643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07800654,0.0293859,0.8097235,0.00005048212,0.00008137541,0.000605784,0.0004636218,0.00002253097,0.0003663505,0.00001239038,0.00003485663,0.08124666],"study_design_scores_gemma":[0.1345998,0.2136124,0.6497141,0.000349051,0.00009581354,0.00005916764,0.001271958,0.00004416175,0.00009448254,0.000009218585,0.00007451521,0.00007533623],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984015,0.00007592276,0.00009101913,0.0003413107,0.000115368,0.0009319327,0.000002955984,0.000005747899,0.00003429674],"genre_scores_gemma":[0.9965549,0.00005686362,0.003108886,0.0001407747,0.0000858634,0.000005765516,0.000006447872,0.00001881589,0.00002173589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1842265,"threshold_uncertainty_score":0.5483084,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04923117680282855,"score_gpt":0.3980623160294409,"score_spread":0.3488311392266123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}